Bortezomib for previously untreated multiple myeloma

Bibliography

• Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-54
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17
   PubMed Web of Science ®Google Scholar
• Delforge M, Blade J, Dimopoulos MA, Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086-95
   PubMed Web of Science ®Google Scholar
• Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 1999;6:303-13
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003;29(Suppl 1):3-9
   PubMed Web of Science ®Google Scholar
• Bross PF, Kane R, Farrell AT, Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004;10:3954-64
   PubMed Web of Science ®Google Scholar
• Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-13
   PubMed Web of Science ®Google Scholar
• Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DM, Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16
   PubMed Web of Science ®Google Scholar
• Hideshima T, Ikeda H, Chauhan D, Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009;114:1046-52
   PubMed Web of Science ®Google Scholar
• Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999;97:431-4
   PubMed Web of Science ®Google Scholar
• An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000;14:1276-83
   PubMed Web of Science ®Google Scholar
• Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009;23:1964-79
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Akiyama M, Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4
   PubMed Web of Science ®Google Scholar
• Politou M, Naresh K, Terpos E, Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta Haematol 2005;114:170-3
   PubMed Web of Science ®Google Scholar
• Ma MH, Yang HH, Parker K, The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44
   PubMed Web of Science ®Google Scholar
• Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10-24
   PubMed Web of Science ®Google Scholar
• Catley L, Weisberg E, Kiziltepe T, Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441-9
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Dillon M, Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009;8:2616-24
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Chen Q, Kuhn DJ, Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007;13:6469-78
   PubMed Web of Science ®Google Scholar
• Cheriyath V, Jacobs BS, Hussein MA. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors. Drugs R D 2007;8(1):12
   PubMedGoogle Scholar
• Delforge M, Terpos E, Richardson PG, Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol 2011;86:372-84
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D, Kokkoris P, Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 2010;21:1561-2
   PubMed Web of Science ®Google Scholar
• Meenaghan T, O'Dwyer M, Hayden P, Home administration of bortezomib: making a difference to myeloma patients' lives. Eur J Oncol Nurs 2010;14:134-6
   PubMed Web of Science ®Google Scholar
• Bortezomib Investigator's Brochure edition 14, version 2 February 2011
   Google Scholar
• Lightcap ES, McCormack TA, Pien CS, Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673-83
   PubMed Web of Science ®Google Scholar
• Reece DE, Sullivan D, Lonial S, Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 2011;67:57-67
   PubMed Web of Science ®Google Scholar
• Moreau P, Coiteux V, Hulin C, Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008;93:1908-11
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-40
   PubMed Web of Science ®Google Scholar
• Pekol T, Daniels JS, Labutti J, Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 2005;33:771-7
   PubMed Web of Science ®Google Scholar
• Quinn DI, Nemunaitis J, Fuloria J, Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet 2009;48:199-209
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Rader M, Ramanathan RK, Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clin Ther 2009;31:2444-58
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson JR, Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005;103:1195-200
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Chanan-Khan A, Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010;28:4976-84
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Kaufman JL, Mehta J, Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604-6
   PubMed Web of Science ®Google Scholar
• Shah JJ, Kuhn DJ, Orlowski RZ. Bortezomib and EGCG: no green tea for you? Blood 2009;113:5695-6
   PubMed Web of Science ®Google Scholar
• Perrone G, Hideshima T, Ikeda H, Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009;23:1679-86
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Stinchcombe TE, Mitchell BS, Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Barlogie B, Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-34
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, De Samblanx HM, Roussou MG, Efficacy of bortezomib plus dexamethasone versus bortezomib monotherapy in patients with relapsed/refractory multiple myeloma: an interim report from an international electronic observational study. ASH Annual Meeting Abstracts 2010;116:3027
   Google Scholar
• Palumbo A, Ambrosini MT, Benevolo G, Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007;109:2767-72
   PubMed Web of Science ®Google Scholar
• Kropff M, Bisping G, Schuck E, Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330-7
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma 2009;50:1096-101
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Jagannath S, Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713-19
   PubMed Web of Science ®Google Scholar
• Cavo M, Rajkumar SV, Palumbo A, International Myeloma Working Group (IMWG) consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem-cell transplantation. Blood 2011; In press
   Web of Science ®Google Scholar
• Harousseau JL, Avet-Loiseau H, Attal M, Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009;27:5720-6
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010;28:2612-24
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P, Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Rosinol L, Hussein M, Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-7
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Mitsiades C, Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518-25
   PubMed Web of Science ®Google Scholar
• Jagannath S, Durie BG, Wolf J, Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-83
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Leleu X, Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498-505
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621-9
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Kendall T, Al-Zoubi A, Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009;27:5015-22
   PubMed Web of Science ®Google Scholar
• Popat R, Oakervee HE, Hallam S, Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008;141:512-16
   PubMed Web of Science ®Google Scholar
• Palumbo A, Gay F, Falco P, Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28:800-7
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf I, van der Holt B, HOVON-65/GMMG-HD4 Randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts 2010;116:40
   Google Scholar
• Reeder CB, Reece DE, Kukreti V, Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23:1337-41
   PubMed Web of Science ®Google Scholar
• Kropff M, Liebisch P, Knop S, DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. Ann Hematol 2009;88:1125-30
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-85
   PubMed Web of Science ®Google Scholar
• Harousseau J-L, Avet-Loiseau H, Facon T, Bortezomib plus dexamethasone (VD) versus reduced-dose bortezomib plus thalidomide plus dexametasone (vTD) as induction treatment prior to autologous stem-cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts 2009;114:354
   Google Scholar
• Rosinol L, Cibeira MT, Mateos MV, A phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib. ASH Annual Meeting Abstracts 2010;116:307
   Google Scholar
• Bensinger WI, Jagannath S, Vescio R, Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Br J Haematol 2010;148:562-8
   PubMed Web of Science ®Google Scholar
• Pineda-Roman M, Zangari M, Haessler J, Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008;140:625-34
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-86
   PubMed Web of Science ®Google Scholar
• Kumar S, Flinn IW, Richardson PG, Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multi-center, randomized, phase 2 EVOLUTION study. ASH Annual Meeting Abstracts 2010;116:621
   Google Scholar
• Ludwig H, Viterbo L, Greil R, Bortezomib, thalidomide, and dexamethasone (VTD) versus VTD plus cyclophosphamide as induction therapy in previously untreated multiple myeloma patients eligible for HDT-ASCT: a randomized phase 2 trial. ASH Annual Meeting Abstracts 2009;114:2312
   Google Scholar
• Kumar S, Giralt S, Stadtmauer EA, Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009;114:1729-35
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Marit G, Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia 2010;24:1233-5
   PubMed Web of Science ®Google Scholar
• Roussel M, Moreau P, Huynh A, Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010;115:32-7
   PubMed Web of Science ®Google Scholar
• Mellqvist U-H, Westin J, Gimsing P, Improved response rate with bortezomib consolidation after high dose melphalan: first results of a nordic myeloma study group randomized phase III trial. ASH Annual Meeting Abstracts 2009;114:530
   Google Scholar
• Ladetto M, Pagliano G, Ferrero S, Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010;28:2077-84
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Liberati AM, Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107-14
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C, Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18
   PubMed Web of Science ®Google Scholar
• Hulin C, Facon T, Rodon P, Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-70
   PubMed Web of Science ®Google Scholar
• Wijermans P, Schaafsma M, Termorshuizen F, Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010;28:3160-6
   PubMed Web of Science ®Google Scholar
• Waage A, Gimsing P, Fayers P, Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010;116:1405-12
   PubMed Web of Science ®Google Scholar
• Beksac M, Haznedar R, Firatli-Tuglular T, Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 2011;86:16-22
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernandez JM, Hernandez MT, Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165-72
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Palumbo A, Richardson PG, Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010;116:3743-50
   PubMed Web of Science ®Google Scholar
• Mateos MV, Richardson PG, Schlag R, Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259-66
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Martinez-Lopez J, Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934-41
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D, Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:5101-9
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-95
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M, Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630-4
   PubMed Web of Science ®Google Scholar
• Ludwig H, Adam Z, Hajek R, Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010;28:4635-41
   PubMed Web of Science ®Google Scholar
• Scheid C, Sonneveld P, Schmidt-Wolf I, Influence of renal function on outcome of VAD or bortezomib, doxorubicin, dexamethasone (PAD) induction treatment followed by high-dose melphalan (HDM): a subgroup analysis from the HOVON-65/GMMG-HD4 randomized phase III trial for newly diagnosed multiple myeloma. ASH Annual Meeting Abstracts 2010;116:2396
   Google Scholar
• Lonial S, Waller EK, Richardson PG, Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106:3777-84
   PubMed Web of Science ®Google Scholar
• San Miguel J, Blade J, Boccadoro M, A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006;11:51-61
   PubMed Web of Science ®Google Scholar
• Perfetti V, Palladini G, Brunetti L, Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor. Eur J Gastroenterol Hepatol 2007;19:599-601
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009;144:895-903
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Mateos MV, Richardson PG, Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 2011;86:23-31
   PubMed Web of Science ®Google Scholar
• Bringhen S, Larocca A, Rossi D, Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745-53
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Sonneveld P, Schuster MW, Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784-90
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Wright J, Moskowitz C, Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84
   PubMed Web of Science ®Google Scholar